Routes of Administration, Duration and Presence/Absence of Comorbid Conditions in Patients With and Without Adverse Events (AEs)
| Patients | Route | Duration | Comorbid Conditions | |||
|---|---|---|---|---|---|---|
| Oral | SL | < 6 mos | ≥ 6 mos | Without | With | |
| With any AE (n=8) | 7 (5-10mg) | 1 (5mg) | 3 | 5 | 3 | 5 |
| Without AE (n=34) | 30 (1-5mg) | 4 (5mg) | 12 | 22 | 15 | 19 |
*SL = sublingual